請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68487
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭謙仁(Chian-Ren Jeng) | |
dc.contributor.author | Susanne Je-Han Lin | en |
dc.contributor.author | 林之涵 | zh_TW |
dc.date.accessioned | 2021-06-17T02:22:41Z | - |
dc.date.available | 2022-08-24 | |
dc.date.copyright | 2017-08-24 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-19 | |
dc.identifier.citation | 1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016, 66(1):7-30.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015, 136(5):E359-386. 3. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE: Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004, 96(3):218-228. 4. Tata JR: One hundred years of hormones. EMBO reports 2005, 6(6):490-496. 5. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al: Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007, 87(3):905-931. 6. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS: Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 1997, 138(11):4613-4621. 7. Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 2000, 21(3):427-433. 8. Deroo BJ, Korach KS: Estrogen receptors and human disease. J Clin Invest 2006, 116(3):561-570. 9. Lukong KE: Understanding breast cancer – The long and winding road. BBA Clinical 2017, 7:64-77. 10. Reis-Filho JS, Pusztai L: Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378(9805):1812-1823. 11. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, et al: Progesterone induces adult mammary stem cell expansion. Nature 2010, 465(7299):803-807. 12. Hagan CR, Lange CA: Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med 2014, 12:32. 13. Brisken C: Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 2013, 13(6):385-396. 14. Daniel CW, Silberstein GB, Strickland P: Direct action of 17 beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res 1987, 47(22):6052-6057. 15. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, et al: Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A 2010, 107(7):2989-2994. 16. Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA: Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol 2015, 54(2):R31-53. 17. Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, Clarke CL: Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 2005, 19(11):2713-2735. 18. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM: Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000, 289(5485):1751-1754. 19. Condon JC, Hardy DB, Kovaric K, Mendelson CR: Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kappaB may contribute to the onset of labor through inhibition of PR function. Mol Endocrinol 2006, 20(4):764-775. 20. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, et al: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986, 319(6050):230-234. 21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182. 22. Graziano C: HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP today 1998, 12(10):1, 14-16. 23. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999, 17(7):1983-1987. 24. Rakha EA, Reis-Filho JS, Ellis IO: Basal-Like Breast Cancer: A Critical Review. J Clin Oncol 2008, 26(15):2568-2581. 25. Gusterson BA, Ross DT, Heath VJ, Stein T: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005, 7(4):143. 26. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al: Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011, 24(2):157-167. 27. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31(1):11-24. 28. Bhargava R, Beriwal S, McManus K, Dabbs DJ: CK5 is more sensitive than CK5/6 in identifying the 'basal-like' phenotype of breast carcinoma. Am J Clin Pathol 2008, 130(5):724-730. 29. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al: Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 30. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352. 31. Sotiriou C, Neo S-Y, McShane LM, Korn EL, Long PM, Jazaeri A, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100(18):10393-10398. 32. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874. 33. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167. 34. Prat A, Ellis MJ, Perou CM: Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol, 9(1):48-57. 35. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A: Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012, 38(6):698-707. 36. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al: Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015, 26(8):1533-1546. 37. Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, et al: Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010, 28(11):1813-1820. 38. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672. 39. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14(6):461-471. 40. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015, 372(8):724-734. 41. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al: Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28(20):3271-3277. 42. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374. 43. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5(1):5-23. 44. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24(9):2206-2223. 45. Gnant M, Thomssen C, Harbeck N: St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care 2015, 10(2):124-130. 46. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR: Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968, 40(2):307-318. 47. Vascellari M, Baioni E, Ru G, Carminato A, Mutinelli F: Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res 2009, 5:39. 48. Sorenmo KU, Worley DR, Goldschmidt MH Withrow.Tumors of the Mammary Gland. In: SJ, Page R, Vail DM: Withrow and MacEwen's small animal clinical oncology. St. Louis: Elsevier; 2013. p.538-552. 49. Zappulli V, Rasotto R, Caliari D, Mainenti M, Pena L, Goldschmidt MH, et al: Prognostic evaluation of feline mammary carcinomas: a review of the literature. Vet Pathol 2015, 52(1):46-60. 50. Soares M, Correia J, Peleteiro MC, Ferreira F: St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol 2016, 37(3):4053-4064. 51. Ito T, Kadosawa T, Mochizuki M, Matsunaga S, Nishimura R, Sasaki N: Prognosis of malignant mammary tumor in 53 cats. J Vet Med Sci 1996, 58(8):723-726. 52. Misdorp W, Romijn A, Hart AA: Feline mammary tumors: a case-control study of hormonal factors. Anticancer Res 1991, 11(5):1793-1797. 53. Hughes K, Dobson JM: Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J 2012, 194(1):19-26. 54. Weijer K, Hart AA: Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 1983, 70(4):709-716. 55. Seixas F, Palmeira C, Pires MA, Bento MJ, Lopes C: Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis. Vet J 2011, 187(1):65-71. 56. Hayes HM, Jr., Milne KL, Mandell CP: Epidemiological features of feline mammary carcinoma. Vet Rec 1981, 108(22):476-479. 57. Seixas F, Palmeira C, Pires MA, Lopes C: Mammary invasive micropapillary carcinoma in cats: clinicopathologic features and nuclear DNA content. Vet Pathol 2007, 44(6):842-848. 58. Overley B, Shofer FS, Goldschmidt MH, Sherer D, Sorenmo KU: Association between ovarihysterectomy and feline mammary carcinoma. J Vet Intern Med 2005, 19(4):560-563. 59. Skorupski KA, Overley B, Shofer FS, Goldschmidt MH, Miller CA, Sorenmo KU: Clinical characteristics of mammary carcinoma in male cats. J Vet Intern Med 2005, 19(1):52-55. 60. Jacobs TM, Hoppe BR, Poehlmann CE, Ferracone JD, Sorenmo KU: Mammary adenocarcinomas in three male cats exposed to medroxyprogesterone acetate (1990-2006). J Feline Med Surg 2010, 12(2):169-174. 61. Mol JA, van Garderen E, Rutteman GR, Rijnberk A: New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. J Steroid Biochem Mol Biol 1996, 57(1-2):67-71. 62. Mol JA, van Garderen E, Selman PJ, Wolfswinkel J, Rijinberk A, Rutteman GR: Growth hormone mRNA in mammary gland tumors of dogs and cats. J Clin Invest 1995, 95(5):2028-2034. 63. Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A: Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci 2005, 79(3):225-232. 64. Martin de las Mulas J, van Niel M, Millan Y, Blankenstein MA, van Mil F, Misdorp W: Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domest Anim Endocrinol 2000, 18(1):111-125. 65. Martin de las Mulas J, Millan Y, Bautista MJ, Perez J, Carrasco L: Oestrogen and progesterone receptors in feline fibroadenomatous change: an immunohistochemical study. Res Vet Sci 2000, 68(1):15-21. 66. Martin de las Mulas J, van Niel M, Millan Y, Ordas J, Blankenstein MA, Van Mil F, Misdorp W: Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Res Vet Sci 2002, 72(2):153-161. 67. Millanta F, Calandrella M, Vannozzi I, Poli A: Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet Rec 2006, 158(24):821-824. 68. Rutteman GR, Blankenstein MA, Minke J, Misdorp W: Steroid receptors in mammary tumours of the cat. Acta endocrinol 1991, 125 Suppl 1:32-37. 69. Hamilton JM, Else RW, Forshaw P: Oestrogen receptors in feline mammary carcinomas. Vet Rec 1976, 99(24):477-479. 70. Johnston SD, Hayden DW, Kiang DT, Handschin B, Johnson KH: Progesterone receptors in feline mammary adenocarcinomas. Am J Vet Res 1984, 45(2):379-382. 71. Martin PM, Cotard M, Mialot J-P, Andre F, Raynaud J-P: Animal models for hormone-dependent human breast cancer. Cancer Chemother Pharmacol 1984, 12(1):13-17. 72. Burrai GP, Mohammed SI, Miller MA, Marras V, Pirino S, Addis MF, et al: Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 2010, 10:156. 73. Soares M, Madeira S, Correia J, Peleteiro M, Cardoso F, Ferreira F: Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization. Breast 2016, 27:44-51. 74. Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M: Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer 2013, 13:403. 75. Maniscalco L, Iussich S, Martin de Las Mulas J, Millan Y, Biolatti B, Sasaki N, et al: Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours. Vet J 2012, 191(1):65-71. 76. Caliari D, Zappulli V, Rasotto R, Cardazzo B, Frassineti F, Goldschmidt MH, et al: Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer. BMC Vet Res 2014, 10:185. 77. Brunetti B, Asproni P, Beha G, Muscatello LV, Millanta F, Poli A, et al: Molecular phenotype in mammary tumours of queens: correlation between primary tumour and lymph node metastasis. J Comp Pathol 2013, 148(2-3):206-213. 78. Mills SW, Musil KM, Davies JL, Hendrick S, Duncan C, Jackson ML, et al: Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Vet Pathol 2015, 52(2):238-249. 79. Misdorp W, Else RW, Hellme’n, et al: Histological classification of mammary tumors of the dog and the cat. In: International Histological Classification of Tumors of Domestic Animals. Vol 7. Washington, DC: Armed Forces Institute of Pathology, American Registry of Pathology; 1999. p.11-56 80. Zappulli V, Caliari D, Rasotto R, Ferro S, Castagnaro M, Goldschmidt M: Proposed classification of the feline 'complex' mammary tumors as ductal and intraductal papillary mammary tumors. Vet Pathol 2013, 50(6):1070-1077. 81. Seixas F, Pires MA, Lopes CA: Complex carcinomas of the mammary gland in cats: pathological and immunohistochemical features. Vet J 2008, 176(2):210-215. 82. Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M: Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol 1998, 119(3):263-275. 83. Soares M, Ribeiro R, Carvalho S, Peleteiro M, Correia J, Ferreira F: Ki-67 as a Prognostic Factor in Feline Mammary Carcinoma: What Is the Optimal Cutoff Value? Vet Pathol 2016, 53(1):37-43. 84. Preziosi R, Sarli G, Benazzi C, Mandrioli L, Marcato PS: Multiparametric survival analysis of histological stage and proliferative activity in feline mammary carcinomas. Res Vet Sci 2002, 73(1):53-60. 85. Preziosi R, Sarli G, Benazzi C, Marcato PS: Detection of proliferating cell nuclear antigen (PCNA) in canine and feline mammary tumours. J Comp Pathol 1995, 113(4):301-313. 86. Castagnaro M, De Maria R, Bozzetta E, Ru G, Casalone C, Biolatti B, Caramelli M: Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas. Res Vet Sci 1998, 65(3):223-226. 87. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF: Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 2005, 65(3):907-912. 88. Millanta F, Calandrella M, Citi S, Della Santa D, Poli A: Overexpression of HER-2 in Feline Invasive Mammary Carcinomas: An Immunohistochemical Survey and Evaluation of Its Prognostic Potential. Vet Pathol 2005, 42(1):30-34. 89. Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V: An Immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Pathol 2011, 144(2-3):170-179. 90. Santos S, Baptista CS, Abreu RM, Bastos E, Amorim I, Gut IG, et al: ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer. PLoS One 2013, 8(12):e83673. 91. Soares M, Correia J, Rodrigues P, Simoes M, de Matos A, Ferreira F: Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques. Microsc Microanal 2013, 19(4):876-882. 92. Maniscalco L, Millan Y, Iussich S, Denina M, Sanchez-Cespedes R, Gattino F, et al: Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. BMC Vet Res 2013, 9:80. 93. Beha G, Muscatello LV, Brunetti B, Asproni P, Millanta F, Poli A, et al: Molecular phenotype of primary mammary tumours and distant metastases in female dogs and cats. J Comp Pathol 2014, 150(2-3):194-197. 94. Gown AM: Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008, 21 Suppl 2:s8-s15. 95. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G: Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human Pathol 2006, 37(9):1217-1226. 96. Ordas J, Millan Y, Dios R, Reymundo C, Martin de las Mulas J: Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007, 7(1):179. 97. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J: ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast cancer Res 2010, 12(4):R56. 98. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134(7):48-72. 99. Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, et al: Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol 2013, 20(1):87-93. 100. Cardazzo B, Zappulli V, Frassineti F, Patarnello T, Castagnaro M, Bargelloni L: Full-length sequence and expression analysis of estrogen receptor alpha mRNA in feline mammary tumors. J Steroid Biochem Mol Biol 2005, 96(2):109-118. 101. Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, et al: Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res 2013, 15(4):R68. 102. Cserni G, Francz M, Kalman E, Kelemen G, Komjathy DC, Kovacs I, et al: Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they? Pathol Oncol Res 2011, 17(3):663-668. 103. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, et al: Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor–Positive Phenotype. J Clin Oncol 2007, 25(30):4772-4778. 104. Chan M, Chang MC, Gonzalez R, Lategan B, del Barco E, Vera-Badillo F, et al: Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS One 2015, 10(7):e0132449. 105. Ng CH, Pathy NB, Taib NA, Mun KS, Rhodes A, Yip CH: The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact. Asian Pac J Cancer Prev 2012, 13(4):1111-1113. 106. Tavares WL, Lavalle GE, Figueiredo MS, Souza AG, Bertagnolli AC, Viana FA, et al: Evaluation of adverse effects in tamoxifen exposed healthy female dogs. Acta Vet Scand 2010, 52:67. 107. Morris JS, Dobson JM, Bostock DE: Use of tamoxifen in the control of canine mammary neoplasia. Vet Rec 1993, 133(22):539-542. 108. Muscatello LV, Sarli G, Beha G, Asproni P, Millanta F, Poli A, et al: Validation of tissue microarray for molecular profiling of canine and feline mammary tumours. J Comp Pathol 2015, 152(2-3):153-160. 109. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11(2):174-183. 110. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103(22):1656-1664. 111. Millanta F, Lazzeri G, Mazzei M, Vannozzi I, Poli A: MIB-1 labeling index in feline dysplastic and neoplastic mammary lesions and its relationship with postsurgical prognosis. Vet Pathol 2002, 39(1):120-126. 112. Dias Pereira P, Carvalheira J, Gartner F: Cell proliferation in feline normal, hyperplastic and neoplastic mammary tissue--an immunohistochemical study. Vet J 2004, 168(2):180-185. 113. Davis BW, Raudsepp T, Pearks Wilkerson AJ, Agarwala R, Schaffer AA, Houck M, et al: A high-resolution cat radiation hybrid and integrated FISH mapping resource for phylogenomic studies across Felidae. Genomics 2009, 93(4):299-304. 114. Winston J, Craft DM, Scase TJ, Bergman PJ: Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours. Vet Comp Oncol 2005 3(1):8-15 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68487 | - |
dc.description.abstract | 人類的乳腺腫瘤在全球都高居女性惡性腫瘤發生率的第一位,且發生人數與死亡人數逐年增加。過去的研究將乳癌當做單一疾病,有不同的組織分型與化療反應,但隨著近年基因體之解碼與蓬勃發展之癌症醫學研究,發現人類乳癌的基因表現有著不同的內在分子亞型,分別呈現了各自的臨床表徵、分子生物學特性與預後的差別,因此在臨床上進行亞型的區分相當具有意義。這幾種內在分子亞型,大致可分為Luminal A, Luminal B, HER2-enriched, Basal-like與Normal breast-like。貓是除了狗之外,少數會自發性長出乳腺腫瘤的家畜動物,而非強行致癌之實驗動物。乳腺腫瘤在母貓為第三常見的腫瘤,僅次於皮膚腫瘤與淋巴肉瘤,且高達85- 95%被診斷為惡性。越來越多研究者提出,貓乳腺腫瘤可作為人類乳腺腫瘤之動物模式,且研究其致癌機制,可以提供許多有價值的資訊。在本研究中,依循了人類腫瘤之分類,對於74個貓惡性乳腺腫瘤檢體進行了分子表型的區分,統計其與各臨床因子、病理組織因子之間的關聯性,並追蹤了51隻貓兩年的預後情形。結果顯示四種分子表型,依多寡順序分別為Luminal B/HER2−(37/74, 50.0%; 22/51, 43.1%)、Luminal B/HER2+(20/74, 27.0%; 16/51, 31.4%)、Luminal A (14/74, 18.9%; 11/51, 21.6%)及Triple negative(3/74, 4.1%; 2/51, 3.9%)。其分佈情形與過往之研究大相逕庭,三陰乳腺腫瘤表型之占比非常低,且主要導因於過高的PR(Progesterone)陽性率(94.6%),此或許與不同的地理位置、貓隻族群不同及荷爾蒙狀態等原因相關,需要進一步研究。此四種分子表型與病理組織分級有著相關性,以Luminal A惡性程度最低,Luminal B/HER2−惡性程度最高。在預後分析部分,雖然分子表型並無顯著的預測效果,但Luminal A之存活時間仍較久,而臨床與病理組織因子中,是否遠端轉移、腫塊潰瘍、臨床分級、病理組織分型、三種病理組織分級(Elston and Ellis、Revised Elston and Ellis、Mitotic-Modified Elston and Ellis grading systems)、淋巴血管轉移與炎症類型都在本研究中有著對預後的預測效果。本研究最終之結果與過去研究並不完全相同,但仍顯示出,貓惡性腫瘤並非性質單一的疾病,且可能在地域分佈上存在著差異。若能進一步探討其中之原因,對於理解貓惡性乳腺腫瘤及進一步對人類乳腺腫瘤的比較病理學,應具有正面意義。 | zh_TW |
dc.description.abstract | Breast cancer is the most common cancer in women worldwide, and the incidence and mortality rates increase year by year. In the past, breast cancer was perceived as a single disease entity with different histological morphologies and chemotherapy responses, but nowadays breast cancer has been divided into several intrinsic molecular subtypes after the unraveling of human genome as well as many significant discoveries. The major intrinsic subtypes include: Luminal A, Luminal B, HER2-enriched, Basal-like and Normal breast-like, which each has its own clinical characteristics, molecular gene expressions, specific biological behavior, and prognosis, making it meaningful to figure out the subgroups clinically. Domestic cats, besides dogs, are the few animal species that will spontaneously develop mammary tumors instead of the laboratorial, artificial animal models. Mammary tumors are the third most common tumor in queens, only secondary to the skin tumors and lymphomas, and up to 85 to 95% cases are diagnosed as malignant cancers. In recent years, more and more researchers have proposed that feline mammary tumors can be used as animal models for human breast cancer. In the present study, we retrospectively classified 74 feline mammary carcinomas into different intrinsic molecular subtypes based on the surrogate immunohistochemical panel from human researches, and the survival status and clinical information were obtained in 51 cats. We have found four subtypes, including Luminal B/HER2− (37/74, 50.0%; 22/51, 43.1%), Luminal B/HER2+(20/74, 27.0%; 16/51, 31.4%), Luminal A (14/74, 18.9%; 11/51, 21.6%) and Triple negative (3/74, 4.1%; 2/51, 3.9%). The considerable low percentage of triple negative subtype, owing to the high positive rate of progesterone receptor (PR) (94.6%), is quite distinct from the previous reports in which it usually serves as the major component. The disagreement may be related to the different geological location, and the different feline breeds with diverse clinical and hormonal status, which need further study. The four subtypes were associated with the histological grades: the Luminal A showed the lowest malignancy, while the Luminal B/HER2− subtype usually exhibited higher grades. In the survival analysis, although the subgroups did not show survival prediction, the Luminal A subtype had the longest overall survival time. The clinical and pathological parameters, such as distant metastasis, tumor ulceration, clinical stage, histopathological classification, three pathological grading systems (Elston and Ellis, Revised Elston and Ellis, Mitotic-Modified Elston and Ellis), lymphovascular invasion, and types of inflammation, were associated to the survival time. In spite of the fact that our results are distinct from previous studies, it still points out the heterogeneous characteristics of feline mammary carcinomas, which may have geological differences. Further clarifying the underlying cause may enable us to know more about the nature of feline mammary tumors and will provide prospective and interesting findings for comparative pathology. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T02:22:41Z (GMT). No. of bitstreams: 1 ntu-106-R03644001-1.pdf: 10264572 bytes, checksum: 367d66ae28cb2435256430664ec863e6 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 中文摘要 I
Abstract III 目錄 V 圖目錄 VIII 表目錄 X 第一章 前言 1 第二章 文獻回顧 1 第一節人類乳腺腫瘤 1 1.1 簡介與流行病學 1 1.2 雌激素受體(Estrogen receptor, ER) 2 1.3黃體素受體(Progesterone receptor, PR) 3 1.4第二型人類表皮生長因子受體(Receptor tyrosine kinase erbB-2, human epidermal growth factor 2, HER2, HER2/neu) 5 1.5 基底角蛋白Basal cytokeratins 與Cytokerain 5 6 1.6 分子表型 7 第二節 貓乳腺腫瘤 11 2.1 貓乳腺腫瘤簡介 11 2.2 流行病學與臨床因子 11 2.3臨床分級 17 2.4 病理組織分型與分級 18 2.5 組織病理與分子標記 20 2.6三陰乳腺腫瘤與分子表型 21 第三章 材料與方法 24 第一節 病例收集 24 第二節 臨床資訊之收集 24 第三節 病理組織評估 24 第四節 Tissue Microarray (TMA)組織微陣列的製作 26 第五節 免疫組織化學染色 26 第六節 染色結果判讀標準 28 6.1 ER、PR與CK5 29 6.2 HER2 29 6.3 Ki67 30 第七節 分子表型分類 32 第八節 統計分析 33 第四章 研究結果 35 第一節 ER、PR、HER2、CK5與Ki67染色結果 35 第二節 分子表型 35 第三節 分子表型與臨床因子之關聯,及臨床資訊之統計結果 36 第四節 分子表型與病理因子之關聯 38 第五節 存活分析 40 第六節 五種染色與臨床、病理組織因子、存活時間之關聯性 42 第五章 討論 43 第一節 分子表型 43 1.1 ER與PR 44 1.2 HER2 49 1.3 Ki67 51 1.4 分子表型與臨床因子、病理組織因子、存活時間之關係 52 第二節 臨床資訊、病理組織因子之統計結果與存活時間之關係 54 第六章 結論 57 第七章 參考文獻 102 | |
dc.language.iso | zh-TW | |
dc.title | 評估貓惡性乳腺腫瘤病理組織分型、分子表型與預後相關性 | zh_TW |
dc.title | Pathological Study and Molecular Phenotyping of Feline Mammary Carcinomas: The Correlation of Phenotypes with Clinical Outcome | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 龐飛(Victor Fei Pang),張惠雯(Hui-Wen Chang),武敬和(Ching-Ho Wu) | |
dc.subject.keyword | 乳腺腫瘤,貓乳腺腫瘤,分子表型,荷爾蒙受體, | zh_TW |
dc.subject.keyword | breast cancer,feline mammary tumor,molecular phenotype,hormone receptor, | en |
dc.relation.page | 112 | |
dc.identifier.doi | 10.6342/NTU201703918 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-20 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 分子暨比較病理生物學研究所 | zh_TW |
顯示於系所單位: | 分子暨比較病理生物學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 10.02 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。